Janssen begins phase III trial of RSV vaccine for older patients

Having received promising results in a phase IIb study of its RSV vaccine, the Johnson and Johnson-owned pharmaceutical company is now initiating a phase III trial to test the candidate on adults aged 60 and up.

Photo: Marta Fernández Jara/AP/Ritzau Scanpix

23,000 people will be included in Janssen's phase III study of its vaccine for respiratory syncytial virus, known as RSV. The trial has just begun according to a press release from the company, which is the pharmaceutical arm of the life science group, Johnson and Johnson.

The phase III trial will investigate the efficacy of the company's vaccine in adults aged 60 years or older, compared to a placebo. The study is being carried out in North America, in addition to select countries throughout Europe, Asia and the Southern Hemisphere.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs